Vaccine resistance movement

(Extraído de vaccineresistancemovement.com)

The road-map leading to all neurological & neuro-developmental disorders traces back to the earliest vaccines administered to babies (HEP B, DTaP, PCV, RV, HIB, IPV, MMR). Timing is the key – a premature breach of the delicate, under-developed “electrical grid network” designed to protect the baby’s brain & nervous system (Myelin Sheath, Blood-Brain Barrier, Meninges). It’s not a stroke of genius to utilize basic detective work of this variety.

The proof is in the toxic overload, resulting in all the current manifestations we are witnessing throughout our communities. The WHO, CDC, NIH & all similar Government Health Departments & Institutions around the world, in collusion with major vaccine manufacturers, are implicated in this fraudulent cover-up of the truth. Please wake up, folks! the ENTIRE vaccine Industry is a fraud, period. Vaccine Resistance Movement

Case in point: The PCV Vaccine PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), part of the standard immunization program throughout the West, is typically administered to babies in 4 stages (2, 4, 6 & 12-15 months) and further given to adults 19-64 with varying chronic conditions (lung, heart, liver or kidney disease; asthma, diabetes, alcoholism/smokers, HIV/AIDS, cancer, damaged/absent spleen). According to the CDC it is ostensibly designed to project against “blood infections, pneumonia, and meningitis, mostly in young children…deafness and brain damage.”

All vaccinated children in the Western hemisphere are now carriers of what is known as MRSA (Methicillin-resistant Staphylococcus aureus/anti-biotic resistant super-bug), due to cross-infection primarily from the routine administering of the Pneumococcal (PCV) Vaccine – in combination with post vaccination anti-biotic & anti-viral drug treatment, an accumulative assault which strips a child of his/her natural anti-biotic resistance whilst infecting them with a host of bacterial serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F); leaving them totally vulnerable to Pneumonia, Myocarditis, Meningitis & even sudden death. The current generation have literally become unwitting hosts to a form of bacterial roulette, an ideal breeding ground for the proliferation & weaponizing of bacterial infections.

This vaccine is also linked to high-grade seizures & chronic infections (ie. ear), again triggered by the series, stemming from the barrage of vaccine derived heavy metals & excipients, resulting in Anaphylaxis, a system-wide allergic & functional breakdown, described as ‘a severe, whole-body allergic reaction to a chemical that has become an allergen‘, and Encephalitis, inflammation of the brain & meninges (Meningoencephalitis) manifesting as ‘diffuse and/or focal neuropsychological dysfunction‘.

‘”I had a baby that was perfectly healthy, happy, okay until she got a shot until she got her vaccine. Thirty, forty hours later, she’s in the hospital having seizures that they can’t stop. You’re not going to tell me it’s not related to the vaccine somehow. It’s hard, it’s very hard. I’m not angry, I’m mad. I guess I’m a little bitter about losing a child. I’m not a little… I’m a lot bitter.” Quote from Ray Graves, father of baby Hayley – who slipped in and out of a coma for 45 days after receiving Prevnar7 (Pneumococcal 7-valent Conjugate Vaccine/Diphtheria CRM197 Protein: Prevnar®), until she died in September, 2001. Tremors shook her little body almost the entire time.

According to Dr. Erdem Cantekin, a medical researcher, one of the leading US experts on earaches, not only are federal regulators issuing bad information, they are also not revealing some of Prevnar’s dangerous side effects. Cantekin says a study by the vaccine’s manufacturer shows seizures happened four times more often in infants given vaccines with Prevnar than children in a control group.

“It [Prevnar] is an ineffective and toxic vaccine. I think the FDA approval of this vaccine is an act of irresponsibility. I think the FDA is following their regular course. They ignore the warnings until many people die, and then it becomes such a public outrage and public problem, they say, ‘Oops, we will take this thing off the market.‘”

‘Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Prevnar® (manufactured by Pfizer/Wyeth), is a sterile solution of saccharides of the capsular antigens of Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F individually conjugated to diphtheria CRM197 protein. Each serotype is grown in soy peptone broth. The individual polysaccharides are purified through centrifugation, precipitation, ultrafiltration, and column chromatography. The polysaccharides are chemically activated to make saccharides which are directly conjugated to the protein carrier CRM197 to form the glycoconjugate. This is effected by reductive amination. CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium. CRM197 is purified through ultrafiltration, ammonium sulfate precipitation, and ion-exchange chromatography. The individual glycoconjugates are purified by ultrafiltration and column chromatography and are analyzed for saccharide to protein ratios, molecular size, free saccharide & protein.’
http://labeling.pfizer.com/showlabeling.aspx?id=134

‘Prevnar 13 (manufactured by Pfizer/Wyeth) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. Prevnar 13 is also indicated for the prevention of otitis media caused by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, and 19A. Prevnar 13, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) is a sterile suspension of saccharides of the capsular antigens of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM197 protein. Each serotype is grown in soy peptone broth. The individual polysaccharides are purified through centrifugation, precipitation, ultrafiltration, and column chromatography. The polysaccharides are chemically activated to make saccharides, which are directly conjugated by reductive amination to the protein carrier CRM197, to form the glycoconjugate. CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extractbased medium. CRM197 is purified through ultrafiltration, ammonium sulfate precipitation, and ion-exchange chromatography. The individual glycoconjugates are purified by ultrafiltration and column chromatography and analyzed for saccharide to protein ratios, molecular size, free saccharide, and free protein.’
http://labeling.pfizer.com/showlabeling.aspx?id=501

The Centers for Disease Control and Prevention (CDC) recommends the vaccine for:
Anyone 65 years of age and older & Adults 19-64 with any of the following conditions:
1. Chronic illnesses such as lung, heart, liver or kidney disease; asthma; diabetes or alcoholism
2. Conditions that weaken the immune system, such as HIV/AIDS, cancer, damaged/absent spleen
3. Cochlear implants or cerebro-spinal fluid (CSF) leaks
4. Adults 19-64 who smoke cigarettes
http://www.adultvaccination.org/doc/pneumo_patient_fact_sheet.pdf

Pneumococcal vaccine. (Minimum age: 6 weeks for pneumococcal conjugate
vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPSV])
• PCV is recommended for all children aged younger than 5 years. Administer
1 dose of PCV to all healthy children aged 24 through 59 months who are
not completely vaccinated for their age.
• A PCV series begun with 7-valent PCV (PCV7) should be completed with
13-valent PCV (PCV13).
• A single supplemental dose of PCV13 is recommended for all children aged
14 through 59 months who have received an age-appropriate series of PCV7.
• A single supplemental dose of PCV13 is recommended for all children aged
60 through 71 months with underlying medical conditions who have received
an age-appropriate series of PCV7.
• The supplemental dose of PCV13 should be administered at least 8 weeks
after the previous dose of PCV7. See MMWR 2010:59(No. RR-11).
• Administer PPSV at least 8 weeks after last dose of PCV to children aged
2 years or older with certain underlying medical conditions, including a
cochlear implant.
http://www.cdc.gov/vaccines/recs/schedules/downloads/child/0-6yrs-schedule-pr.pdf

‘Children between the 2nd and 6th birthdays with medical conditions such as: – sickle cell disease, – a damaged spleen or no spleen, – cochlear implants, – diabetes, – HIV/AIDS or other diseases that affect the immune system (such as cancer, or liver disease), or -chronic heart or lung disease, or who take medications that affect the immune system, such as immunosuppressive drugs or steroids, should get 1 dose of PCV 13 doses of PCV7 or PCV13 before age 2 years), or 2 doses of PCV13 (if they have received 2 or fewer doses of PCV7 or PCV13). A dose of PCV13 may be administered to children and adolescents 6 through 18 yrs of age who have certain medical conditions, even if they have previously received PCV7/23.’
http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-pcv.pdf

Based on data acquired from the ongoing Vaccine Adverse Events Reporting System (VAERS) Prevnar has been directly linked to ‘28,317 adverse reactions since it was approved in 2000, including 558 deaths, 555 life threatening conditions, 238 permanent disabilities, 2,584 hospitalisations, 101 prolonged hospitalisations, 8,166 emergency room cases and 16,155 “not serious”).

Long-term adverse reactions to PCV Vaccine include the following:

1. An increase in the incidence of pneumonia caused by bacteria NOT covered by these vaccines
2. An increase in middle-ear infections due to bacteria not linked to pneumonia
3. The emergence of “superbugs” (MRSA) that are resistant to vaccines.
http://www.flu-treatments.com/prevnar-vaccine.html

Dutch babies die after PCV vaccine: ‘The PCV vaccine, which is supposed to protect infants and young children against pneumonia, was recently linked to three unexplained infant deaths in the Netherlands. On 5 November 2009, the Dutch government announced that three babies died within two weeks – between one and 11 days – of receiving the vaccine. This is the Prevnar pneumonia conjugate vaccine or PCV, commonly called PCV vaccine, made by drug giant Pfizer.

The response of the Dutch government is hard to comprehend and to accept. Initial press reports sait it banned ONE BATCH of the vaccine but later reports clarified that Pfizer “quarantined” the batch, which contained about 110,000 doses. One would expect that when something as serious as this happens, the health authorities concerned would, at the very least, suspend its vaccination programme pending the results of further investigations. But no. The vaccination programme continued with other batches of the same PCV vaccine. Equally hard to accept is this statement from spokeswoman for the Dutch health institute RIVM: “On average about 5 to 10 deaths are reported annually after babies get vaccines. We now have three cases in a short period; that is unusual, and the reason for suspending the batch.”’
http://www.flu-treatments.com/pcv-vaccine.html

Resistant ‘Superbugs’ Create Need for Novel Antibiotics: New Pneumococcal Conjugate Vaccine – ‘There are now two types of pneumococcal vaccine: pneumococcal polysaccharide vaccine (PneumovaxAE, Pnu-ImmuneAE) and pneumococcal conjugate vaccine (PrevnarAE). Pneumococcal polysaccharide vaccine has been available since 1977 and has been recommended approximately every 5-10 years for older adults and certain at-risk populations. However, this vaccine has not been effective in children under 2 years of age. In February 2000, the FDA approved another form of this vaccine, the pneumococcal conjugate vaccine (PrevnarAE).

In the past, the pneumococcal polysaccharide vaccine was formulated based on certain epidemic serotypes of S. pneumoniae. With the emergence of resistant strains of the organism, a change in the vaccine has been necessary. The pneumococcal conjugate vaccine has been developed which can impart immunity against drug resistant strains of S. pneumoniae. Ex panded use of the newly formulated conjugate pneumococcal vaccine can provide protection against approximately 80% of resistant pneumococcal strains. This form of the vaccine is recommended for children under 2 years of age and other at-risk patient populations. Individuals with risk factors for pneumococcal infection can receive both forms of the vaccine (CDC, 2003).

Superbug resistance is escalating within the clinical setting and community at large. In novative antibiotic strategies are still lacking within the pharmaceutical industry to keep pace with the growing resistance, with a glaring absence of any novel class of antibacterial drug in the United States for decades. Most new antibiotics are chemical modifications of existing drugs and are quickly outsmarted by the bacteria in the environment. Clinicians are challenged by some strains of bacteria which are resistant to essentially all available antimicrobial agents. New antibiotics must be used with precision after the infectious organism is identified by culture and sensitivity testing. Using the exact antibiotic which specifically targets the identified organism is a key strategy to limit bacterial resistance.’
http://www.medscape.com/viewarticle/554935_6

Epidemiology and risk factors for Staphylococcus aureus colonization in children in the post-PCV7 era: ‘In Massachusetts, S. aureus and MRSA colonization remained stable from 2003-04 to 2006-07 among children <7 years despite widespread use of pneumococcal conjugate vaccine. S. aureus nasal colonization varies by age and is inversely correlated with recent antibiotic use.’
http://www.ncbi.nlm.nih.gov/pubmed/19594890

Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006: ‘…while the incidence of pneumococcal meningitis and bacteraemia due to non-vaccine strains increased from 9.4 to 17.5 cases per 100,000 in this time period. The incidence in older children and adults did not decrease. Further expansion of PCV coverage is expected to increase the impact of the vaccination in both children and adults. However, the fact that cases caused by vaccine serotypes have been partially substituted by cases of non-vaccine serotypes is likely to reduce the overall benefit of PCV in France, should this early observation be confirmed in the future.

If, on the other hand, the partial substitution of the cases that are caused by vaccine serotypes with cases caused by non-vaccine serotypes, that was observed in our early analysis in young children, is confirmed in the coming years, this would lead to a reduction of the positive impact of PCV vaccination in France.’
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18962

Note: “There’s more risk for MRSA (methicillin-resistant Staphylococcus aureus) to become invasive in the presence of flu or other viruses. These deaths in co-infected children are a warning sign. This is especially alarming given the rising rates of MRSA infections being carried widely among children. It is not common in the U.S. to lose a previously healthy child to pneumonia. Unfortunately, these children had necrotizing pneumonia eating away at their tissue and killing off whole areas of the lung. They looked like immunocompromised patients in the way MRSA went through their body. It’s not that flu alone can’t kill – it can – but in most cases children with flu alone survived…The more antibiotics we take, the more we colonize ourselves with antibiotic-resistant organisms such as MRSA.” Adrienne G. Randolph, MD, Division of Critical Care Medicine at Children’s Hospital Boston

‘During the 2009 H1N1 influenza pandemic, many previously healthy children became critically ill, developing severe pneumonia and respiratory failure, sometimes fatal. The largest nationwide investigation to date of influenza in critically ill children, led by Children’s Hospital Boston, found one key risk factor: Simultaneous infection with methicillin-resistant Staphylococcus aureus (MRSA) increased the risk for flu-related mortality 8-fold among previously healthy children. Moreover, almost all of these co-infected children were rapidly treated with vancomycin, considered to be appropriate treatment for MRSA. The fact that they died despite this treatment is especially alarming given the rising rates of MRSA carriage among children in the community.

While most of the children critically ill with H1N1 had one or more chronic health conditions that increased their risk, such as asthma, neurologic disorders or compromised immune systems, 251 children (30 percent) were previously healthy. Among these otherwise healthy children, the only risk factor that was identified for death from influenza was a presumed diagnosis of MRSA co-infection in the lung – which increased the risk for mortality 8-fold (P<0.0001). 88 percent of the children admitted to the ICU received Tamiflu (oseltamivir) during their stay, but only 6 percent had received it prior to hospital admission…The study also found that most of the MRSA co-infected children who died had received vancomycin promptly at or before ICU admission.’ Children’s Hospital, Boston
http://www.childrenshospital.org/newsroom/Site1339/mainpageS1339P791.html

Note: ‘88 percent of the children admitted to the ICU received Tamiflu (oseltamivir) during their stay…’

Eugenics mandate moving full steam ahead: ‘To appreciate how far we’ve come you need to remember where we started. Consider the situation with pneumococcal conjugate vaccines (PCV) in 2003. At that time, developing country access to these vaccines seemed almost unthinkable. The vaccine had only been routinely used in the U.S. for three years, and the manufacturer was struggling to supply American children who paid top dollar prices. Access to affordable supplies of this vaccine was out of the question. In addition, the World Health Organization (WHO) had not yet recommended the vaccine for use and most developing countries had little appreciation for the burden of pneumococcal disease in their countries. Finally, our track record in vaccine access was generally lame, with 15 years or more passing before poor countries accessed the same vaccines as richer ones.

To their credit, GAVI and its Board recognized the importance of pneumococcal vaccines and established GAVI’s PneumoADIP at the Johns Hopkins Bloomberg School of Public Health to accelerate their introduction in the world’s poorest countries. With four years of funding and a small, dedicated team, PneumoADIP aimed to establish, communicate and deliver the value of pneumococcal vaccination by providing the evidence that was needed to make this vaccine a priority.’
http://www.huffingtonpost.com/dr-orin-levine/access-to-the-power-of-va_b_1136823.html